InfiCure Bio has recently been granted a patent in the United States for its preclinical model.
At the same time a study describing the basics of the model has been accepted for publication in online journal Scientific Reports.
“We are delighted and anticipate that thanks to this attention we will strengthen our position in the market and expect even more customers to show interest in our model”, says Sofia Mayans, CEO of Inficure Bio.
The patent approval opens up further business opportunities, while protecting the model from competitors. “Today the USA is our largest market, so the approval of this patent means that we can develop our business there even further,” says Mayans.
Photo of Sofia Mayans and Dan Holmberg, InfiCure Bio: Malin Grönborg